30 closest matches · ranked by relevance
Non-functioning Pituitary Adenoma
Primary: Percentage of Participants With Non-functioning Pituitary Adenomas (NFPA) Who Achieve Tumor Volume Reduction of at Least 20% After 24 Weeks (FAS) — 16.7 percentage of…
Non-functioning Pituitary Adenomas · Prolactinomas
Primary: Tumor Volume Changes for NFPA and Prolactin Level Changes for Prolactinoma — 3.8; 29.35 cmˆ3 — p=<0.05
Pituitary Adenoma · Pituitary Diseases
Primary: Number of Participants With Adrenal Insufficiency — 2; 1 Participants
Pituitary Adenoma
Primary: Percentage of Responders (Primary Medical Treatment in Arm 1, Primary Surgical Treatment in Arm 2) — 6.7; 50 percentage of participants
Pituitary Adenomas · Prolactinomas
Primary: Change in Tumor Volume — 10 Percent volume
Acromegaly
Primary: Percentage of Patients With Relevant Reduction in Pituitary Tumour Volume (as Measured by MRI) From Baseline Volume (Visit 1) to Week 48 (After 12 Injections at Visit 5)…
Pituitary Tumor · Pain
Primary: Comparison of Mean Pain Scores Between Two Arms (Measured Every 4 Hours Over 48 Hour) — 1.7; 2.8 0-10 units on a scale
Cushing Disease
Primary: Percentage of Responders With Mean Urinary Free Cortisol (UFC) Within Normal Limits — 22.2 percentage of responders
Growth Hormone Deficiency · Traumatic Brain Injury
Primary: Maximum Oxygen Uptake at Baseline. — 29.0 mL/kg/min
Growth Hormone Deficiency · Septo-Optic Dysplasia · Hypopituitarism
Primary: Change in Anthropometric Measures Over Time — 1.97; -0.61; 1.39; 1.22 Z-score
Endocrine Tumors
Primary: Progression-Free Survival (PFS) — NA; 72 Weeks — p=<0.001
Parathyroid Disease
Primary: Detection Rate of Parathyroid Adenomas of Anti-3-[18F]FACBC Modality — 80 percentage of adenomas detected
Cushing Syndrome · Endocrine Disease
Primary: Sensitivity of Imaging Modalities for the Detection of ACTH-secreting Non-pituitary Tumor in Patients — 96.3; 77.1; 66.7; 100 percentage of patients
Acromegaly
Primary: Percentage of Participants With Growth Hormone (GH) and Insulin-like Growth Factor 1 (IGF-1) Observed Response by Dose Class — 20; 28.6; 14.3; 23.1 percentage of…
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
Acromegaly · Pituitary Gigantism
Primary: Total-group Response Rate at Month 3 — 18.2 Percentage of participants
Primary Amenorrhea With Hypogonadotropic Hypogonadism
Primary: Ovulation Rate — 1; 4; 5; 9 Participants — p=0.0120
Non Functioning Entero-pancreatic Endocrine Tumour
Primary: Adverse Events — 40; 46; 86 participants with any TEAEs
Neuroendocrine Tumors · Carcinoid Tumors
Primary: Progression-free Survival (PFS) at One Year — 11 months
Acromegaly
Primary: Core Phase: Percentage of Participants With Mean GH < 1 g/L and IGF-1 < ULN at Week 36 by Previous Treatment and Overall — 14.6; 13.8; 15.1; 14.6 Percentage of…
Idiopathic Intracranial Hypertension
Primary: Mean Change in Perimetric Mean Deviation — 1.43; 0.71 dB — p=0.05
Cushings Disease
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability Profile of Pasireotide s.c. — 11; 13; 34; 54 Participants
Acromegaly
Primary: Effect of Pegvisomant on Colon Tissue p53 Expression — 330.57 ng/mL
Hyperparathyroidism · Hypercalcemia · Parathyroid Neoplasm
Primary: Type of Hyperparathyroidism — 90; 276; 19; 61 Participants
Acromegaly
Primary: IGF-1 Levels — 424 ng/mL — p=< 0.05
Neuroendocrine Carcinoma of the Lung and Thymus
Primary: Percentage of Participants Progression-free at 9 Months Based on Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1) — 0; 0; 0; 2.4 percentage of participants
Neuroendocrine Tumors
Primary: Time to Tumor Progression Documented by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) — 14.3; 6.0 Months
Neurofibromatosis 2 · Meningioma
Primary: Radiographic Response Rate for Target Meningioma — 1 target meningiomas
Hyperprolactinemia · Prolactinoma
Primary: Percentage of Subjects That Achieved PRL Normalization as Defined by a Serum Prolactin Level Less Than 25ng/mL at Any Time Point During the Study Treatment Period. — 6…
Panhypopituitarism
Primary: Fatigue Impact Scale — -22.9; 2.2 units on a scale — p=0.08